Gene · 51428
Papers1,824
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,824
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Germline Variants and Characteristic Features of Hereditary Hematological Malignancy Syndrome. | Int J Mol Sci | 2024 | 38203823 | PubTator, text mining | PubMed |
| Lung adenocarcinomas with isolated TP53 mutation: A comprehensive clinical, cytopathologic and molecular characterization. | Cancer Med | 2024 | 38164123 | PubTator, text mining | PubMed |
| Nucleic acid-induced inflammation on hematopoietic stem cells. | Exp Hematol | 2024 | 38151171 | PubTator, text mining | PubMed |
| Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study. | Lancet Haematol | 2024 | 38135373 | PubTator, text mining | PubMed |
| Deciphering expression and variants in cardiovascular disease genes among heart failure population for precision medicine. | ESC Heart Fail | 2024 | 38131165 | PubTator, text mining | PubMed |
| Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. | Am J Hematol | 2024 | 38071734 | PubTator, text mining | PubMed |
| Sequential tumor molecular profiling identifies likely germline variants. | Genet Med | 2024 | 38054407 | PubTator, text mining | PubMed |
| Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML. | Br J Haematol | 2024 | 38016923 | PubTator, text mining | PubMed |
| Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation. | Transplant Cell Ther | 2024 | 37913908 | PubTator, text mining | PubMed |
| Multifunctional glycolipids as multi-targeting therapeutics for neural regeneration. | Neural Regen Res | 2024 | 37843195 | PubTator, text mining | PubMed |
| Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients. | Br J Haematol | 2024 | 37710381 | PubTator, text mining | PubMed |
| The heritability of blood-based biomarkers related to risk of Alzheimer's disease in a population-based sample of early old-age men. | Alzheimers Dement | 2024 | 37622539 | PubTator, text mining | PubMed |
| Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia. | Biomedicines | 2023 | 38255170 | PubTator, text mining | PubMed |
| Recent advancements in targeted protein knockdown technologies-emerging paradigms for targeted therapy. | Explor Target Antitumor Ther | 2023 | 38213543 | PubTator, text mining | PubMed |
| PD-L1+ diffuse large B-cell lymphoma with extremely high mutational burden and microsatellite instability due to acquired PMS2 mutation. | Cold Spring Harb Mol Case Stud | 2023 | 38199780 | PubTator, text mining | PubMed |
| Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential. | Front Oncol | 2023 | 38162500 | PubTator, text mining | PubMed |
| Cellular RNA and DNA sensing pathways are essential for the dose-dependent response of human monocytes to ionizing radiation. | Front Immunol | 2023 | 38152396 | PubTator, text mining | PubMed |
| At the Crossroads of the cGAS-cGAMP-STING Pathway and the DNA Damage Response: Implications for Cancer Progression and Treatment. | Pharmaceuticals (Basel) | 2023 | 38139802 | PubTator, text mining | PubMed |
| Genetic Characteristics of Patients with Young-Onset Myelodysplastic Neoplasms. | J Clin Med | 2023 | 38137719 | PubTator, text mining | PubMed |
| Two-Time Multiplexed Targeted Next-Generation Sequencing Might Help the Implementation of Germline Screening Tools for Myelodysplastic Syndromes/Hematologic Neoplasms. | Biomedicines | 2023 | 38137443 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51428/papers?page=9